Evidence map›Paper›PMID 27160784›Full record

ReviewExpert review of vaccines2016

Ebola virus disease candidate vaccines under evaluation in clinical trials.

Karen A Martins, Peter B Jahrling, Sina Bavari, Jens H Kuhn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Vaccines for epidemic infections and the role of CEPI.Human vaccines & immunotherapeutics · 2017
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Karen A Martinsa United States Army Medical Research Institute of Infectious Diseases , Fort Detrick , Frederick , MD , USA.
Peter B Jahrlingb Integrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Fort Detrick , Frederick , MD , USA.
Sina Bavaria United States Army Medical Research Institute of Infectious Diseases , Fort Detrick , Frederick , MD , USA.
Jens H Kuhnb Integrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Fort Detrick , Frederick , MD , USA.

Funding

NIAID NIH HHS HHSN272200700016I
6 · The paper itself

Abstract

Filoviruses are the etiological agents of two human illnesses: Ebola virus disease and Marburg virus disease. Until 2013, medical countermeasure development against these afflictions was limited to only a few research institutes worldwide as both infections were considered exotic due to very low case numbers. Together with the high case-fatality rate of both diseases, evaluation of any candidate countermeasure in properly controlled clinical trials seemed impossible. However, in 2013, Ebola virus was identified as the etiological agent of a large disease outbreak in Western Africa including almost 30,000 infections and more than 11,000 deaths, including case exportations to Europe and North America. These large case numbers resulted in medical countermeasure development against Ebola virus disease becoming a global public-health priority. This review summarizes the status quo of candidate vaccines against Ebola virus disease, with a focus on those that are currently under evaluation in clinical trials.

Indexed as

Clinical Trials as TopicEbola VaccinesHemorrhagic Fever, EbolaHumansEbola VaccinesCandidate vaccineclinical trialebolavirusEbola virusEbola virus diseaseEBOVEVDFiloviridaefilovirusMCMmedical countermeasurevaccine

Identifiers

PMID27160784
PMCPMC5026048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.